These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16644557)

  • 1. Design of nevirapine derivatives insensitive to the K103N and Y181C HIV-1 reverse transcriptase mutants.
    Saparpakorn P; Hannongbua S; Rognan D
    SAR QSAR Environ Res; 2006 Apr; 17(2):183-94. PubMed ID: 16644557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantum computational analysis for drug resistance of HIV-1 reverse transcriptase to nevirapine through point mutations.
    He X; Mei Y; Xiang Y; Zhang DW; Zhang JZ
    Proteins; 2005 Nov; 61(2):423-32. PubMed ID: 16114038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.
    Alcaro S; Alteri C; Artese A; Ceccherini-Silberstein F; Costa G; Ortuso F; Bertoli A; Forbici F; Santoro MM; Parrotta L; Flandre P; Masquelier B; Descamps D; Calvez V; Marcelin AG; Perno CF; Sing T; Svicher V
    ChemMedChem; 2011 Dec; 6(12):2203-13. PubMed ID: 21953939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bridge water mediates nevirapine binding to wild type and Y181C HIV-1 reverse transcriptase--evidence from molecular dynamics simulations and MM-PBSA calculations.
    Treesuwan W; Hannongbua S
    J Mol Graph Model; 2009; 27(8):921-9. PubMed ID: 19414275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138.
    Ren J; Nichols CE; Stamp A; Chamberlain PP; Ferris R; Weaver KL; Short SA; Stammers DK
    FEBS J; 2006 Aug; 273(16):3850-60. PubMed ID: 16911530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docking of non-nucleoside inhibitors: neotripterifordin and its derivatives to HIV-1 reverse transcriptase.
    Zhou Z; Madrid M; Madura JD
    Proteins; 2002 Dec; 49(4):529-42. PubMed ID: 12402361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docking-MM-GB/SA and ADME screening of HIV-1 NNRTI inhibitor: nevirapine and its analogues.
    Sengupta D; Verma D; Naik PK
    In Silico Biol; 2008; 8(3-4):275-89. PubMed ID: 19032162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase.
    Zhou Z; Madrid M; Evanseck JD; Madura JD
    J Am Chem Soc; 2005 Dec; 127(49):17253-60. PubMed ID: 16332074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3D-QSAR models on clinically relevant K103N mutant HIV-1 reverse transcriptase obtained from two strategic considerations.
    San Juan AA
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1181-94. PubMed ID: 18155520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel theoretically designed HIV-1 non-nucleoside reverse transcriptase inhibitors derived from nevirapine.
    Liu J; He X; Zhang JZ
    J Mol Model; 2014 Oct; 20(10):2451. PubMed ID: 25234608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of interaction of novel indolylarylsulfone derivatives with K103N and Y181I mutant HIV-1 reverse transcriptase in complex with its substrates.
    Samuele A; Bisi S; Kataropoulou A; La Regina G; Piscitelli F; Gatti V; Silvestri R; Maga G
    Antivir Chem Chemother; 2011 Nov; 22(3):107-18. PubMed ID: 22095519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational approaches for the design of effective human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitors.
    Ribone SR; Quevedo MA; Madrid M; Briñón MC
    J Chem Inf Model; 2011 Jan; 51(1):130-8. PubMed ID: 21133347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
    Benjahad A; Croisy M; Monneret C; Bisagni E; Mabire D; Coupa S; Poncelet A; Csoka I; Guillemont J; Meyer C; Andries K; Pauwels R; de Béthune MP; Himmel DM; Das K; Arnold E; Nguyen CH; Grierson DS
    J Med Chem; 2005 Mar; 48(6):1948-64. PubMed ID: 15771439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based design, parallel synthesis, structure-activity relationship, and molecular modeling studies of thiocarbamates, new potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of phenethylthiazolylthiourea derivatives.
    Ranise A; Spallarossa A; Cesarini S; Bondavalli F; Schenone S; Bruno O; Menozzi G; Fossa P; Mosti L; La Colla M; Sanna G; Murreddu M; Collu G; Busonera B; Marongiu ME; Pani A; La Colla P; Loddo R
    J Med Chem; 2005 Jun; 48(11):3858-73. PubMed ID: 15916438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors.
    Ren J; Nichols C; Bird L; Chamberlain P; Weaver K; Short S; Stuart DI; Stammers DK
    J Mol Biol; 2001 Sep; 312(4):795-805. PubMed ID: 11575933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution of K103N and/or Y181C HIV-1 mutations by exposure to zidovudine and non-nucleoside reverse transcriptase inhibitors.
    Torti C; Pozniak A; Nelson M; Hertogs K; Gazzard BG
    J Antimicrob Chemother; 2001 Jul; 48(1):113-6. PubMed ID: 11418520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of human immunodeficiency virus type 1 synergistic inhibition by reverse transcriptase mutations.
    Basavapathruni A; Vingerhoets J; de Béthune MP; Chung R; Bailey CM; Kim J; Anderson KS
    Biochemistry; 2006 Jun; 45(23):7334-40. PubMed ID: 16752922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flexible docking of pyridinone derivatives into the non-nucleoside inhibitor binding site of HIV-1 reverse transcriptase.
    Medina-Franco JL; Rodríguez-Morales S; Juárez-Gordiano C; Hernández-Campos A; Jiménez-Barbero J; Castillo R
    Bioorg Med Chem; 2004 Dec; 12(23):6085-95. PubMed ID: 15519154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future.
    De Clercq E
    Chem Biodivers; 2004 Jan; 1(1):44-64. PubMed ID: 17191775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study on the interaction between HIV reverse transcriptase and its non-nucleoside inhibitor nevirapine by capillary electrophoresis.
    Chen W; Li W; Ling X; Wang X; Liu J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Jun; 878(20):1714-7. PubMed ID: 20457546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.